ADA-friendly PDF: 22FC106-Nanoknife-CT-FS-F-Web

Clinical Trials at Fox Chase Cancer Center: Intermediate Risk Prostate Cancer

A Pivotal study to evaluate the use of the NanoKnife System as a focal therapy option for prostate cancer patients. This open-label study will assess the safety and effectiveness of the device when used to ablate prostate tissue in intermediate-risk prostate cancer patients.